Solid Biosciences (SLDB) Net Income towards Common Stockholders (QoQ) (2017 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn |
| 10 | Solid Biosciences | 713.77 Mn | 333.09 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16.66% |
| Dec 31, 2025 | -4.92% |
| Sep 30, 2025 | -16.37% |
| Jun 30, 2025 | -2.56% |
| Mar 31, 2025 | 0.59% |
| Dec 31, 2024 | -15.51% |
| Sep 30, 2024 | -30.13% |
| Jun 30, 2024 | -4.13% |
| Mar 31, 2024 | -17.96% |
| Dec 31, 2023 | 3.07% |
| Sep 30, 2023 | 14.61% |
| Jun 30, 2023 | 17.98% |
| Mar 31, 2023 | 8.11% |
| Dec 31, 2022 | -61.95% |
| Sep 30, 2022 | 18.70% |
| Jun 30, 2022 | 0.90% |
| Mar 31, 2022 | -35.74% |
| Dec 31, 2021 | -3.44% |
| Sep 30, 2021 | 3.57% |
| Jun 30, 2021 | -10.64% |
| Mar 31, 2021 | 20.89% |
| Dec 31, 2020 | -0.55% |
| Sep 30, 2020 | -11.90% |
| Jun 30, 2020 | 28.87% |
| Mar 31, 2020 | 16.66% |
| Dec 31, 2019 | -9.28% |
| Sep 30, 2019 | -10.18% |
| Jun 30, 2019 | 10.71% |
| Mar 31, 2019 | -35.92% |
| Dec 31, 2018 | -15.25% |
| Sep 30, 2018 | -5.78% |
| Jun 30, 2018 | -13.25% |
| Mar 31, 2018 | -9.59% |
| Dec 31, 2017 | -7.27% |
| Sep 30, 2017 | -19.40% |
| Jun 30, 2017 | -80,692.86% |